Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
filingDate |
2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2012-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2012-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-101108642-B1 |
titleOfInvention |
Antibodies that specifically bind to epidermal growth factor receptor |
abstract |
The present invention relates to an antibody that specifically binds to an epidermal growth factor receptor (EGFR). Since the antibody of the present invention exhibits excellent binding ability and neutralizing effect on the epidermal growth factor receptor, the epidermal growth factor receptor It can be used in a composition for treating cancer associated with signaling through.n n n n Epidermal growth factor receptor, antibody, complementarity determining region, cancer, antibody library, panning |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180137502-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015099513-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102128556-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101782632-B1 |
priorityDate |
2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |